| Literature DB >> 30552279 |
Ingrid Larsson1,2, Maria L E Andersson2,3.
Abstract
OBJECTIVES: The aims were to identify patients with rheumatoid arthritis (RA) who had stopped drinking alcohol and compare them with patients drinking alcohol, and to explore reasons for stopping drinking alcohol.Entities:
Keywords: qualitative research; rheumatology
Mesh:
Year: 2018 PMID: 30552279 PMCID: PMC6303608 DOI: 10.1136/bmjopen-2018-024367
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Descriptives of patients who stopped drinking alcohol (group 1) and those who did not stop drinking alcohol (group 2), median (min-max)
| Group 1 | Group 2 | P value | |
| N | 86 | 1423 | |
| Age | 69 (36–90) | 66 (23–95) | 0.011 |
| Gender, % female | 58 | 71 | 0.015 |
| Disease duration (year) | 9 (3–17) | 8 (3–17) | 0.813 |
| Hazardous drinkers (AUDIT C) | 60% | 67% | 0.403 |
| SJC(28) (0–28) | 1 (0–28) | 1 (0–26) | 0.199 |
| TJC(28) (0–28) | 4 (0–28) | 3 (0–28) | 0.079 |
| HAQ (0–3) | 1.00 (0–2.75) | 0.50 (0–3.00) | <0.001 |
| EQ5D (0–1) | 0.69 (−0.02–1.00) | 0.76 (−0.59–1.00) | <0.001 |
| PatGA (0–10) | 5 (0–10) | 3 (0–10) | <0.001 |
| Pain (0–10) | 5 (0–10) | 3 (0–10) | <0.001 |
| Fatigue (0–10) | 6 (0–10) | 4 (0–100) | 0.006 |
| Comparison of treatment between groups | |||
| No DMARD or biologics | 33% | 23% | |
| DMARD | 48% | 54% | 0.087* |
| Biologics | 19% | 23% | |
*Overall p value calculated by χ2test for treatment between group 1 and 2.
AUDIT-C, Alcohol Use Disorder Investigation Test-Consump; DMARD, disease-modifying antireumatic drug; EQ5D, EuroQol five dimensions; HAQ, Health Assessment Questionnaire; PatGA, patient global assessment; SJC(28), swollen joint count (28 joints); TJC(28), tender joint count (28 joints).